Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CalciMedica, Inc. (CALC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies, CalciMedica uses its filings to report financial results, corporate actions, and material developments related to programs such as its Auxora™ clinical trials in acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP).
Key documents available through EDGAR and summarized here include Form 10-K annual reports and Form 10-Q quarterly reports, which provide detailed discussions of CalciMedica’s business, risk factors, pipeline status, and financial condition. Form 8-K current reports capture specific events such as quarterly earnings press releases, amendments to equity incentive plans approved at the annual meeting, and changes to at-the-market equity offering capacity under the company’s agreement with H.C. Wainwright & Co.
Investors can also monitor S-3 and S-8 registration statements and related exhibits that describe securities offerings and share-based compensation plans, as well as any Form 4 insider transaction reports that may be filed by directors and officers. These filings help clarify how CalciMedica finances its clinical-stage operations, including the use of at-the-market offerings and a disclosed credit facility, and how equity incentives are structured for employees and leadership.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, such as changes in cash runway commentary, updates on the KOURAGE trial, or modifications to capital-raising programs. Real-time updates from EDGAR ensure that new CalciMedica filings appear quickly, while structured views of 10-Ks, 10-Qs, 8-Ks, registration statements, and Form 4 reports allow users to focus on the specific regulatory information most relevant to their analysis of CALC.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.
CalciMedica, Inc. reported that Eric W. Roberts, its chief business officer, director, and a ten percent owner, made an open-market purchase of common stock. On September 15, 2025, a Roth IRA account for his benefit bought 3,400 shares at a weighted average price of $2.6779 per share, with trade prices ranging from $2.65 to $2.70. Following this transaction, that Roth IRA held 81,650 common shares. The filing also updates his other direct and indirect common stock positions, including shares held directly and through multiple IRA and Valence Investments SPV entities.
CalciMedica, Inc. director and chief business officer Eric W. Roberts reported an open-market purchase of 5,000 shares of common stock at $3.12 per share. The shares are held indirectly through an FMTC Custodian Roth IRA for his benefit. The filing also updates his direct and other indirect common stock holdings across several custodial and investment entities.
CalciMedica insider purchase and holdings summary. Eric W. Roberts, who is listed as a director, a 10% owner and Chief Business Officer, reported a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488 (price range $2.75–$3.21). The filing lists total beneficial ownership following the reported transactions across multiple accounts and entities: 73,250 shares (FMTC Custodian Roth IRA), 179,706 shares disposed, 49,894 shares (Oppenheimer custodian Roth IRA), 10,661 shares (IRA Financial Trust), 356,989 shares (Valence Investments SPV IV, LLC), 66,228 shares (Valence Investments SPV V, LLC), and 316,109 shares (Valence Investments SPV VI, LLC). The filer signed through an attorney-in-fact.
CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.
The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.
CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.
The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.
CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.
The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.
CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.
The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.
CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.
CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.
CalciMedica director, chief business officer, and 10% owner Eric W. Roberts reported open‑market purchases of CalciMedica common stock through a Roth IRA. On August 28, 2025, an FMTC‑custodied Roth IRA for his benefit bought 9,200 shares at a weighted average price of $2.863, with trade prices ranging from $2.75 to $2.92. On August 29, 2025, the same Roth IRA bought an additional 800 shares at $2.74 per share, bringing that account’s holdings to 70,907 shares.
After these transactions, Roberts is shown as directly owning 179,706 shares and indirectly owning additional CalciMedica shares through multiple custodial and investment vehicles, including Roth IRAs and Valence Investments special purpose vehicles.
CalciMedica, Inc. director, chief business officer, and 10% owner Eric W. Roberts reported an open-market purchase of 3,508 shares of common stock on August 21, 2025 at a weighted average price of $2.7928 per share. The purchased shares are held indirectly through an FMTC Custodian Roth IRA for his benefit, which now holds 60,907 shares after the transaction.
CalciMedica insider filing shows purchases and an option exercise increasing reported holdings. Eric W. Roberts reported purchases of 1,000 shares on 08/19/2025 at $2.79 and 2,000 shares on 08/20/2025 at $2.72. He also exercised an employee stock option for 15,000 shares at an exercise price of $1.53 on 08/20/2025.
The filing lists multiple custodial and indirect holdings across Roth IRA accounts and several Valence Investments SPVs, and shows 57,750 derivative securities reported as beneficially owned following the transactions.
CalciMedica insider purchase reported: The company's Chief Medical Officer, Sudarshan Hebbar, reported buying 9,563 shares of CalciMedica, Inc. (ticker: CALC) on 08/19/2025 at a weighted average purchase price of $2.8194, with individual trade prices ranging from $2.74 to $2.86. After the transaction, the reporting person beneficially owned 61,539 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/21/2025 and discloses that breakdowns by price per lot are available upon SEC staff request.